



Life Sciences Financing Summary Europe


December 2015

Swiss ADC Therapeutics raised EUR 73.3m, making September the second best month totalling EUR 305m in European Biotech financing. After a record month of July and a rather weak August month in which only Merus BV raised EUR 73m prior to its IPO in October, September of 2015, had again 11 rounds of financing and surpassed the average financing levels seen in the previous 12 months with the second largest round of the last 12 months.

In addition to ADC Therapeutics, the largest private rounds in Biotech (Therapeutics and Diagnostics) in the past two months were Danish Symphogen's EUR 67.5m in October followed by Spanish Laboratorios Sanifit's EUR 36.6m also in September.

Continue reading below to learn more about the financing highlights of September and October 2015 in the European Life Science industry.

Europe - Biotech Therapeutic and Diagnostics Financing Rounds



Source: BiotechgateBiotechgate.com

*The graph contains only financing rounds of private & independent biotech therapeutic and diagnostic companies. Financing amounts and number of rounds from previous months may alter as new information on financing rounds is received and/or new tranches to existing financing rounds are added.

Selected financing highlights: companies raising funds

September 2015

ADC Therapeutics Secured EUR 73.3m (USD 80m) Financing to Progress its Pipeline

Lausanne, Switzerland – based ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, announced on the 2nd of September that it had raised EUR 73.3m (USD 80m) through a private placement of equity. New investors include leading European and US-based investors alongside founding investor Auvén Therapeutics and participation from AstraZeneca. *Source: news release.*

Sanifit Raises EUR 36.6m to Advance Lead Drug Candidate

Palma de Mallorca, Spain based – Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company, announced on the 8th of September 2015 that it had raised EUR 36.6m in a Series C financing round. The company is focused on the development of SNF472, an experimental drug for the treatment of cardiovascular diseases linked to calcification in patients with End Stage Renal Disease (ESRD) undergoing haemodialysis.

This round of fundraising will enable Sanifit to advance its lead drug candidate, SNF472, through Phase IIb proof of concept for the treatment of cardiovascular diseases linked to calcification in ESRD and to complete phase II/III for calciphylaxis.

The investment was led by Ysios Capital and supported by a substantial syndicate of new investors including Lundbeckfond Ventures, Forbion Capital Partners, Gilde Healthcare, Edmond de Rothschild Investment Partners, "la Caixa" and BaxterVentures. Existing shareholders also supported the series C round. *Source: news release.*

October 2015

Symphogen announced closing of a EUR 67.5m convertible debt facility.

Copenhagen, Denmark – based Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced on the 22nd of October the closing of a EUR 67.5 m convertible debt facility, secured from existing investors, led by Novo A/S and the Danish pension fund PKA. The proceeds will be used to progress the company's pipeline, specifically Sym004, a novel antibody mixture and its lead clinical program currently in a multi-center Phase 2b study in metastatic colorectal cancer patients with disease resistance or refractory to anti-EGFR antibody therapies. *Source: news release.*

Selected financing highlights – investors in September, October 2015


The following investors have made investments into European Life Science companies through September and October 2015:

- Atlas Venture
- Arthurian Life Sciences
- Baxter Healthcare
- Danish pension fund PKA
- Edmond de Rothschild Investment Partners
- Endeavour Vision
- Forbion Capital Partners
- Gilde Healthcare
- HealthEquity
- Inserm Transfert Initiative
- La Caixa
- Lundbeckfond Ventures
- Nefrona Foundation
- New Enterprise Associates
- Novo A/S
- Schroder & Co. Banque SA
- Somtobir
- Versant Ventures
- VI Partners
- Woodford Investment Management
- Ysios Capital

Quarterly biotech equity financing breakdown by lead product development phase (Biotech Therapeutics & Diagnostics)

The second quarter of 2015 for private investments in Biotech (therapeutics and diagnostics) was solely comprised of investments in companies whose most advanced project was either in preclinical stage or in Phase II. Specifically, 60% of all investments made during the second quarter were in companies whose most advanced project was in preclinical stage, while the remaining 40% were in Phase II projects.

During the third quarter of 2015, financing of companies with lead projects in Phase I and III re-emerged, constituting 17% and 8% respectively. The Phase II segment increased its share of financing to 58%, reaching the highest proportion of the previous four quarters.



The graph above shows the proportion of financing rounds by most advanced project phase in the therapeutics and diagnostics category per quarter, including only private companies

September, October 2015 financing rounds summary

Company Name	Sector	Amount (in Million EUR)	Ownership	Country
Acacia Pharma	Biotechnology - Therapeutics and Diagnostics	204.9	Publicly listed on stock exchange	United Kingdom
Grifols, S.A.	Pharma	100.0	Publicly listed on stock exchange	Spain
CeQur SA	Medical Technology	89.0	Private / independent	Switzerland
Advanced Accelerator Applications SA	Pharma	75.0	Private / independent	France
ADC Therapeutics, Inc	Biotechnology - Therapeutics and Diagnostics	73.3	Private / independent	Switzerland
Symphogen A/S	Biotechnology - Therapeutics and Diagnostics	67.5	Private / independent	Denmark
Merus B.V.	Biotechnology - Therapeutics and Diagnostics	53.5	Publicly listed on stock exchange	Netherlands
Laboratoris Sanifit	Biotechnology - Therapeutics and Diagnostics	36.6	Private / independent	Spain
BIOM'UP	Medical Technology	31.3	Private / independent	France
Therachon	Biotechnology - Therapeutics and Diagnostics	31.2	Private / independent	France
reViral Ltd	Biotechnology - Therapeutics and Diagnostics	28.7	Private / independent	United Kingdom
Novadip Biosciences	Biotechnology - Therapeutics and Diagnostics	28.0	Private / independent	Belgium
Asceneuron SA	Biotechnology - Therapeutics and Diagnostics	27.5	Private / independent	Switzerland
Replimune Ltd.	Biotechnology - Therapeutics and Diagnostics	26.7	Private / independent	United Kingdom
AMO Pharma Limited	Biotechnology - Therapeutics and Diagnostics	22.3	Private / independent	United Kingdom
Minoryx Therapeutics	Biotechnology - Therapeutics and Diagnostics	19.7	Private / independent	Spain
Minoryx Therapeutics	Biotechnology - Therapeutics and Diagnostics	19.4	Private / independent	Spain
Dryzon Genomics	Biotechnology - Therapeutics and Diagnostics	16.9	Private / independent	Spain
Euroscreen SA	Biotechnology - Therapeutics and Diagnostics	16.0	Private / independent	Belgium
Apitope International NV	Biotechnology - Therapeutics and Diagnostics	12.0	Private / independent	Belgium
InteRNA Technologies B.V.	Biotechnology - Therapeutics and Diagnostics	9.4	Private / independent	Netherlands
Oasmia Pharmaceutical AB	Biotechnology - Therapeutics and Diagnostics	8.5	Publicly listed on stock exchange	Sweden
Sequana Medical AG	Medical Technology	8.3	Private / independent	Switzerland
Can-Fite BioPharma	Biotechnology - Therapeutics and Diagnostics	8.0	Publicly listed on stock exchange	Israel
Creo Medical Limited	Medical Technology	7.5	Private / independent	United Kingdom
Rosetta Genomics, Ltd.	Biotechnology - Therapeutics and Diagnostics	7.1	Publicly listed on stock exchange	Israel

Luxendo GmbH	Medical Technology	6.0	Private / independent	Germany
Neuromod Devices Ltd	Medical Technology	5.5	Private / independent	Ireland
saniona	Pharma	5.1	Publicly listed on stock exchange	Denmark
NEO New Oncology AG	Biotechnology / R&D Services	5.0	Private / independent	Germany
Coramaze technologies GmbH	Medical Technology	4.5	Private / independent	Germany
NightBalance B.V.	Medical Technology	4.0	Private / independent	Netherlands
SmartZyme	Biotechnology / R&D Services	3.6	Private / independent	Israel
Biometrics GmbH	Biotechnology / R&D Services	3.1	Private / independent	Germany
Univercells SA	Biotechnology - Therapeutics and Diagnostics	2.9	Private / independent	Belgium
Nuritas	Biotechnology - other	2.9	Private / independent	Ireland
Audion Therapeutics	Biotechnology - Therapeutics and Diagnostics	2.5	Private / independent	Netherlands
Desktop Genetics	Biotechnology / R&D Services	1.9	Private / independent	United Kingdom
TrakCel Limited	Biotechnology / R&D Services	1.8	Private / independent	United Kingdom
Mission Therapeutics Ltd	Biotechnology - Therapeutics and Diagnostics	1.7	Private / independent	United Kingdom
Biocartis NV	Biotechnology / R&D Services	1.4	Publicly listed on stock exchange	Belgium
Venneos GmbH	Medical Technology	1.0	Private / independent	Germany
Esperite N.V.	Biotechnology / R&D Services	0.8	Publicly listed on stock exchange	Netherlands
Genovis AB	Biotechnology / R&D Services	0.6	Publicly listed on stock exchange	Sweden
Computomics	Biotechnology - other	0.5	Private / independent	Germany
4SC AG	Biotechnology - Therapeutics and Diagnostics	0.5	Publicly listed on stock exchange	Germany
Congenica Ltd.	Biotechnology / R&D Services	0.4	Private / independent	United Kingdom
Mind the Byte, S.L.	Biotechnology / R&D Services	0.2	Private / independent	Spain
Mind the Byte ApS	Biotechnology / R&D Services	0.2	Private / independent	Denmark
ZECLINICS	Biotechnology / R&D Services	0.1	Private / independent	Spain
NovoCure Limited	Biotechnology - Therapeutics and Diagnostics	0.0	Publicly listed on stock exchange	United Kingdom
Nabriva Therapeutics AG	Biotechnology - Therapeutics and Diagnostics	0.0	Private / independent	Austria



About this summary

The Life Sciences Financing Summary is published on a bi-monthly basis by Venture Valuation and Fit for Health 2.0 and can be downloaded for free either from our newsletter or from the website <http://www.fitforhealth.eu/>

The data used for this summary is taken from Venture Valuation's global Biotech and life science database Biotechgate. Biotechgate is a popular source for life sciences company and licensing deals information. If you are interested in learning more, please do not hesitate to contact us and to apply for a trial.

[Click here to learn more about Biotechgate »](#)

Venture Valuation
Kasernenstrasse 11
8004 Zurich
Switzerland

Phone: +41 (43) 321 86 60
Web: www.venturevaluation.com
Email: info@venturevaluation.com

Copyright © 2015 Venture Valuation VV Ltd. All rights reserved. This report is provided for information purposes only. All information regarding financing rounds, deal summaries and merger and acquisition transactions was obtained from company websites or industry newsletters including Fiercebiotech, OnBioVC, and SECA. The above information can also be accessed on the Biotechgate website. All graphical information was provided via Biotechgate. While the information contained herein has been obtained from sources deemed reliable, Venture Valuation VV Ltd makes no guarantees that it is accurate, complete, timely, or sequential. For more information about Biotech companies, including deal, licensing and financing round details, please visit the Biotechgate website at www.biotechgate.com